Arecor to present abstract of ultra-rapid acting insulin formulation at EASD virtual meeting

“We believe that AT247’s superior profile will improve both treatment and healthcare outcomes for people living with Type 1 diabetes,” said chief executive Sarah Howell

Arecor -

Arecor Limited will tomorrow present the successful results of a clinical trial of its ultra-rapid acting insulin formulation at a prestigious industry conference.

The biopharmaceutical company’s phase-one study compared the pharmacokinetics (PK), pharmacodynamics (PD) and safety of its AT247 insulin formulation in comparison to insulin aspart, NovoRapid, and fast insulin aspart, Fiasphas.

READ: Arecor says insulin formulation passes landmark with successful phase 1 study

A report of the trial has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual meeting on Tuesday, September 22 at 1.30pm UK time.

AT247 is an investigational novel meal-time insulin formulation that aims to significantly accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels.

It has been designed to move through the body, shown via rates of PK and PD, in a way that more closely matches the physiological insulin mealtime response of a person without diabetes.  

“Presenting the successful results of our Phase 1 study of AT247 at EASD demonstrates the clear potential for our ultra-rapid acting insulin,” said Arecor’s chief executive officer, Sarah Howell. 

“We believe that AT247’s superior profile will improve both treatment and healthcare outcomes for people living with Type 1 diabetes.  

“As treatment delivery systems continue to evolve, we believe that AT247’s favourable profile over current treatments may play a pivotal role in advancing the delivery of care, with the potential to enable the artificial pancreas, which could significantly reduce the burden of self-management  for people living with diabetes.”

Abstract #55 is available online.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

2 days, 9 hours ago

2 min read